疫苗使用政策制定作为发达国家疫苗创新与研发的驱动因素
本文回顾过去200年疫苗对公共卫生的明确影响,并分析美国、英国、加拿大和澳大利亚在已获批疫苗推荐使用路径上的相似性,包括对疾病流行病学、疾病负担与严重程度、疫苗免疫原性/效力/安全性、项目可行性、公众需求及成本效果的专家审查。文章指出未来疫苗开发还需考虑免疫持久性、群体保护优化、项目可行性与改进、公众对疫情病原体的担忧,以及HIV和抗菌药物耐药病原体等难以治疗疾病的重大社会负担。
要点
- 美英加澳对已获批疫苗的推荐路径相似,均包括专家审查疾病负担、疫苗特性、项目可行性与成本效果。
- 未来疫苗开发需关注免疫持久性、群体保护优化、项目改进及公众对疫情病原体的信心。
- 驱动未来疫苗创新与生产面临巨大经济障碍,可能需要成本减缓策略和各方协同努力。
核心结论
- 过去200年疫苗对公共卫生产生了明确影响,包括发病率和死亡率下降,在经济发达国家最为明显。
- 未来疫苗开发预计将以高度工程化疫苗为主,包括针对非传染性疾病的疫苗。
- 驱动未来疫苗创新与生产面临巨大经济障碍,随着可用方法、技术和监管路径变得更加复杂,可能需要成本减缓策略以及政府、私营组织和公私合作伙伴关系的集中协同努力来持续推动疫苗技术与开发的重大进展。
研究设计与样本
- 本文为综述,检索范围未在原文摘要中报告。
主要发现
- 过去200年疫苗对公共卫生产生了明确影响,包括发病率和死亡率下降,在经济发达国家最为明显。
- 美国、英国、加拿大和澳大利亚对已获批疫苗的推荐使用路径相似,包括专家审查疾病流行病学、疾病负担与严重程度、疫苗免疫原性/效力/安全性、项目可行性、公众需求以及日益增加的成本效果。
- 未来疫苗开发可能还需考虑的其他属性包括:改进疫苗(如百日咳疫苗)的免疫持久性;更强调优化群体保护而非仅直接保护;项目实施的可行性、改进(如通用流感疫苗的开发);与埃博拉和寨卡病毒等疫情病原体相关的公众担忧/信心/恐惧;以及应对HIV和抗菌药物耐药病原体等难以治疗疾病的重大社会负担。
关键数值与推荐
- 美国、英国、加拿大和澳大利亚对已获批疫苗的推荐路径相似,包括专家审查疾病流行病学、疾病负担与严重程度、疫苗免疫原性/效力/安全性、项目可行性、公众需求以及日益增加的成本效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the past 200years, vaccines have had unmistakable impacts on public health including declines in morbidity and mortality, most markedly in economically-developed countries. Highly engineered vaccines including vaccines for conditions other than infectious diseases are expected to dominate future vaccine development. We examine immunization vaccine policy as a driver of vaccine innovation and development. The pathways to recommendation for use of licensed vaccines in the US, UK, Canada and Australia have been similar, including: expert review of disease epidemiology, disease burden and severity; vaccine immunogenicity, efficacy and safety; programmatic feasibility; public demand; and increasingly cost-effectiveness. Other attributes particularly important in development of future vaccines are likely to include: duration of immunity for improved vaccines such as pertussis; a greater emphasis on optimizing community protection rather than direct protection only; programmatic implementation, feasibility, improvements (as in the case of development of a universal influenza vaccine); public concerns/confidence/fears related to outbreak pathogens like Ebola and Zika virus; and major societal burden for combating hard to treat diseases like HIV and antimicrobial resistant pathogens. Driving innovation and production of future vaccines faces enormous economic hurdles as available approaches, technologies and regulatory pathways become more complex. As such, cost-mitigating strategies and focused, aligned efforts (by governments, private organizations, and private-public partnerships) will likely be needed to continue to spur major advances in vaccine technologies and development.
引用
- Seib K, Pollard AJ, de Wals P, et al. Policy making for vaccine use as a driver of vaccine innovation and development in the developed world. Vaccine. 2017. PMID: 28253995. doi:10.1016/j.vaccine.2016.10.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。